The tubulysin analogue KEMTUB10 induces apoptosis in breast cancer cells via p53, Bim and Bcl-2

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 9, 2015, Pages 1575-1583

  Lamidi, Oluwafunmilayo F ^a   Sani, Monica ^b,c   Lazzari, Paolo ^b   Zanda, Matteo ^c,d   Fleming, Ian N ^a  

^a Aberdeen Biomedical Imaging Centre   (United Kingdom)

^b KemoTech srl   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anti mitotic; Apoptosis; Bcl 2; Breast cancer; p53; Tubulysin

Indexed keywords

BIM PROTEIN; KEMTUB 10; PROTEIN BCL 2; PROTEIN P53; TETRAPEPTIDE; TUBULIN; TUBULYSIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MEMBRANE PROTEIN; OLIGOPEPTIDE; ONCOPROTEIN; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CELL CYCLE PHASE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MCF 7 CELL LINE; POLYMERIZATION; PRIORITY JOURNAL; WESTERN BLOTTING; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG SCREENING; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939260749     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1921-6     Document Type: Article

References (31)

1. Allan LA, Clarke PR (2007) Phosphorylation of Caspase-9 by CDK1/Cyclin B1 Protects Mitotic Cells against Apoptosis. Mol Cell 26(2):301–310
2. Blagosklonny MV, Fojo T (1999) Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83(2):151–156
3. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L (1998) p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273(20):11995–11998
4. Blagosklonny MV, Robey R, Sheikh MS, Fojo T (2002) Paclitaxel-induced fasl-independent apoptosis and slow (non-apoptotic) cell death. Cancer Biol Ther 1(2):113–117
5. Brenton JD, Carey LA, Ahmed A, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29):7350–7360
6. Dawson S, Rueda OM, Aparicio S, Caldas C (2013) A new genome-driven integrated classification of breast cancer and its implications. EMBO J 32(5):617–628
7. Fleming IN, Hogben M, Frame S, McClue SJ, Green SR (2008) Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res 14(13):4326–4335
8. Gascoigne KE, Taylor SS (2009) How do anti-mitotic drugs kill cancer cells? J Cell Sci 122(15):2579–2585
9. Green SR, Choudhary AK, Fleming IN (2010) Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer 103(9):1391–1399
10. Hait WN, Yang JM (2006) The individualization of cancer therapy: the unexpected role of p53. Trans Am Clin Climatol Assoc 117:85–101 discussion 101
11. Haldar S, Jena N, Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92(10):4507–4511
12. Herrmann J, Elnakady YA, Wiedmann RM, Ullrich A, Rohde M, Kazmaier U, Vollmar AM, Müller R (2012) Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy. PLoS One 7(5):e37416
13. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90
14. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56(4):816–825
15. Kaur G, Hollingshead M, Holbeck S, Schauer-Vukašinović V, Camalier RF, Dömling A, Agarwal S (2006) Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J 396(2):235–242
16. Khalil MW, Sasse F, Lünsdorf H, Elnakady YA, Reichenbach H (2006) Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. ChemBioChem 7(4):678–683
17. Kutuk O, Letai A (2010) Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ 17(10):1624–1635
18. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C (2012) Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 38(7):890–903
19. Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8(5):379–393
20. Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K (2007) BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol 178(2):283–296
21. Panvichian R, Orth K, Day ML, Day KC, Pilat MJ, Pienta KJ (1998) Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 58(20):4667–4672
22. Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, Paolicchi A, Zunino F (1998) Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol 9(4):423–430
23. Sasse F, Steinmetz H, Heil J, Hofle G, Reichenbach H (2000) Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. J Antibiot 53(9):879–885
24. Shajahan AN, Dobbin ZC, Hickman FE, Dakshanamurthy S, Clarke R (2012) Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal Kinase (JNK). J Biol Chem 287(21):17682–17692
25. Shaulian E, Zauberman A, Ginsberg D, Oren M (1992) Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 12(12):5581–5592
26. Smith TAD, Sharma RI, Thompson AM, Paulin FEM (2006) Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 47(9):1525–1530
27. Smith TAD, Zanda M, Fleming IN (2013) Hypoxia stimulates 18F-Fluorodeoxyglucose uptake in breast cancer cells via Hypoxia inducible Factor-1 and AMP-activated protein kinase. Nucl Med Biol 40(6):858–864
28. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van De Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale A (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874
29. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R (1996) Cisplatin, camptothecin, and taxol sensitivities of cells with p53- associated multidrug resistance. Mol Pharmacol 50(6):1536–1540
30. Wu GS, El-Deiry WS (1996) p53 and chemosensitivity [2]. Nat Med 2(3):255–256
31. Zhou X, Sang M, Liu W, Gao W, Xing E, Lü W, Xu Y, Fan X, Jing S, Shan B (2012) LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53. Life Sci 91(9–10):358–363